SCHEMBL5258017

SCHEMBL5258017

O=C(O)/C(=C\c1c[nH]c2ncccc12)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
CHEK1 O14757 2/20 0.47
CAMKK2 Q96RR4 2/20 0.47
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
CLK1 P49759 1/20 0.43
DYRK1A Q13627 1/20 0.43
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
MAP2K1 Q02750 1/20 0.41
AAK1 Q2M2I8 1/20 0.40
CDC7 O00311 4/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
PRKACA P17612 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
HIPK2 Q9H2X6 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5258020 1.00 KMT2A (0.51) KMT2ACHEK1CAMKK2MEN1POLB
SCHEMBL5258776 0.90 KMT2A (0.56) KMT2ACHEK1CAMKK2DYRK1AMAP2K1
SCHEMBL5258775 0.90 KMT2A (0.56) KMT2ACHEK1CAMKK2DYRK1AMAP2K1
SCHEMBL5263254 0.90 KMT2A (0.56) KMT2ACHEK1CAMKK2DYRK1AMAP2K1
SCHEMBL5260626 0.89 KMT2A (0.50) KMT2ACHEK1CAMKK2CLK1DYRK1A
SCHEMBL5258140 0.89 KMT2A (0.50) KMT2ACHEK1CAMKK2CLK1DYRK1A
SCHEMBL5261929 0.89 KMT2A (0.50) KMT2ACHEK1CAMKK2CLK1DYRK1A
SCHEMBL5261932 0.89 KMT2A (0.50) KMT2ACHEK1CAMKK2CLK1DYRK1A
SCHEMBL5260881 0.89 KMT2A (0.52) KMT2ACHEK1CAMKK2MEN1POLB
SCHEMBL5260884 0.89 KMT2A (0.52) KMT2ACHEK1CAMKK2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 KMT2A 1011/4885CHEK1 337/4885CAMKK2 2052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.